Discussions

Recombinant Anti-CD16 EGFR scIgG is designed to be expressed as two chains; each chain has the same units as their parental IgG antibodies, anti-CD16 and anti-EGFR IgGs. The two chains form heterodimers via Fc KIH technology. This BsAb can retarget NK cells toward tumor cells. It is designed for the research of Head and neck cancer, Colorectal cancer (CRC), Glioblastoma multiforme (GBM), Squamous cancer, glioblastoma, medulloblastoma, Non-small cell lung cancer (NSCLC), Renal cell cancer (RCC), and solid tumor therapy.